STOCK TITAN
  1. Home
  2. Financials
  3. NAMS
  4. Revenue

NewAmsterdam Pharma Company N.V. (NAMS) Revenue by Year

NAMS

NewAmsterdam Pharma Company N.V. generated $22.5M in revenue in fiscal year 2025. This represents a decrease of 50.6% from the prior fiscal year. Over the trailing 12 months, Q3 FY2025 through Q2 FY2026, the same line adds up to $7.1M in revenue. The table below carries 5 fiscal years, from 2021 to 2025, and the quarters NewAmsterdam Pharma Company N.V. has filed alongside them.

FY2025 annual
Revenue $22.5M
YoY -50.6%
Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Currency USD

Annual figures, oldest first. Point at a bar to read its period.

NAMS Revenue by Fiscal Year

Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.

MetricTTMFY2510-KFY2410-KFY2310-KFY2210-KFY2110-K
Revenue$7.1M$22.5M-50.6%$45.6M+223.4%$14.1M-86.3%$102.7MN/A

TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings.

NAMS Revenue by Quarter

Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.

MetricQ2'2610-QQ1'2610-QQ4'2510-QQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-KQ3'2410-QQ2'2410-QQ1'2410-QQ4'2310-KQ3'2310-Q
Revenue$3.7M-80.7%$3.0M+2.1%$32K-99.7%$348K-98.8%$19.1M+740.1%$3.0M+112.6%$12.8M+1490.5%$29.1M+889.8%$2.3M+32.7%$1.4M-83.8%$803K$2.9M

What revenue means

Revenue is everything the company billed its customers over the period, counted before any cost of running the business comes out of it.

More NewAmsterdam Pharma Company N.V. financials

Frequently Asked Questions

What was NewAmsterdam Pharma Company N.V.'s revenue in fiscal year 2025?

NewAmsterdam Pharma Company N.V. generated $22.5M in revenue in fiscal year 2025.

How fast is NewAmsterdam Pharma Company N.V.'s revenue growing?

NewAmsterdam Pharma Company N.V. (NAMS) revenue fell by 50.6% year over year, from $45.6M to $22.5M in fiscal year 2025.

What is NewAmsterdam Pharma Company N.V.'s revenue over the last twelve months?

NewAmsterdam Pharma Company N.V. (NAMS) reported $7.1M in revenue over the trailing 12 months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings.

NewAmsterdam Pharma Company N.V. (NAMS) reported $3.7M in revenue in Q2 2026. This represents a decrease of 80.7% from the same quarter a year earlier.

Revenue is everything the company billed its customers over the period, counted before any cost of running the business comes out of it. This page lists what NewAmsterdam Pharma Company N.V. (NAMS) reported on that line in every period on record.